 |
|
|
| |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB)
Has Durable Efficacy and Differentiated Safety Compared to Efavirenz/Emtricitabine/Tenofovir DF (ATR)
in Treatment-naïve HIV-1 Infected Patients:
Week 96 Results
|
| |
| |
Reported by Jules Levin
Eleventh International Congress on Drug Therapy in HIV Infection
11-15 November, 2012, Glasgow, UK
A Zolopa1, JE Gallant2, C Cohen3, P Sax4, E DeJesus5, A Mills6, D Wohl7,
HC Liu8, MS Rhee8, J Szwarcberg8,
1Stanford University, Palo Alto, CA, US; 2Johns Hopkins School of Medicine, Baltimore, MD, US; 3Community Research Initiative of
New England, Boston, MA, US; 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 5Orlando Immunology
Center, Orlando, FL, US; 6Anthony Mills MD, Inc., Los Angeles, CA, US;
7University of North Carolina, Chapel Hill, NC, US;
8Gilead Sciences, Foster City, CA, US
|
| |
|
|
|
|
|
